A detailed history of Glen Eagle Advisors, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 3,429 shares of LLY stock, worth $2.9 Million. This represents 0.57% of its overall portfolio holdings.

Number of Shares
3,429
Previous 705 386.38%
Holding current value
$2.9 Million
Previous $54.5 Million 5592.33%
% of portfolio
0.57%
Previous 0.05%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$724.87 - $909.04 $1.97 Million - $2.48 Million
2,724 Added 386.38%
3,429 $3.1 Billion
Q1 2024

Jul 03, 2024

BUY
$592.2 - $792.28 $1.92 Million - $2.57 Million
3,247 New
3,247 $2.53 Billion
Q4 2023

Aug 13, 2024

SELL
$525.19 - $619.13 $82,980 - $97,822
-158 Reduced 4.94%
3,038 $1.77 Billion
Q3 2023

Aug 13, 2024

SELL
$434.7 - $599.3 $524,248 - $722,755
-1,206 Reduced 27.4%
3,196 $1.72 Billion
Q2 2023

Aug 13, 2024

BUY
$350.74 - $468.98 $32,618 - $43,615
93 Added 2.16%
4,402 $2.06 Billion
Q1 2023

Aug 13, 2024

BUY
$310.63 - $364.82 $268,694 - $315,569
865 Added 25.12%
4,309 $1.48 Billion
Q4 2022

Aug 13, 2024

BUY
$321.55 - $374.67 $398,400 - $464,216
1,239 Added 56.19%
3,444 $1.26 Billion
Q3 2022

Aug 13, 2024

BUY
$296.48 - $337.87 $366,449 - $417,607
1,236 Added 127.55%
2,205 $713 Million
Q2 2022

Aug 13, 2024

BUY
$278.73 - $327.27 $15,887 - $18,654
57 Added 6.25%
969 $314 Million
Q1 2022

Aug 13, 2024

SELL
$234.69 - $291.66 $1,642 - $2,041
-7 Reduced 0.76%
912 $261 Million
Q4 2021

Aug 13, 2024

SELL
$224.85 - $279.04 $13,940 - $17,300
-62 Reduced 6.32%
919 $254 Million
Q3 2021

Aug 13, 2024

BUY
$221.6 - $272.71 $23,489 - $28,907
106 Added 12.11%
981 $227 Million
Q1 2021

Aug 13, 2024

BUY
$164.32 - $212.72 $10,680 - $13,826
65 Added 8.02%
875 $163 Million
Q4 2020

Aug 13, 2024

SELL
$130.46 - $172.63 $317,931 - $420,699
-2,437 Reduced 75.05%
810 $137 Million
Q3 2020

Aug 13, 2024

SELL
$146.22 - $169.13 $1,315 - $1,522
-9 Reduced 1.11%
799 $118 Million
Q2 2020

Aug 13, 2024

BUY
$136.42 - $164.18 $409 - $492
3 Added 0.37%
808 $133 Million
Q1 2020

Aug 13, 2024

BUY
$119.05 - $147.35 $2,857 - $3,536
24 Added 3.07%
805 $112 Million
Q4 2019

Aug 13, 2024

BUY
$106.92 - $132.43 $8,660 - $10,726
81 Added 11.57%
781 $103 Million
Q2 2019

Aug 13, 2024

BUY
$110.79 - $129.32 $10,525 - $12,285
95 Added 15.7%
700 $77.6 Million
Q1 2019

Aug 13, 2024

SELL
$111.31 - $131.02 $294,081 - $346,154
-2,642 Reduced 81.37%
605 $78.5 Million
Q3 2018

Aug 13, 2024

SELL
$85.86 - $107.31 $8,586 - $10,731
-100 Reduced 14.18%
605 $64.9 Million
Q1 2018

Aug 14, 2024

SELL
$74.21 - $87.6 $188,641 - $222,679
-2,542 Reduced 78.29%
705 $54.5 Million
Q1 2018

Aug 13, 2024

SELL
$74.21 - $87.6 $1,261 - $1,489
-17 Reduced 2.35%
705 $54.5 Million
Q3 2017

Aug 13, 2024

SELL
$77.07 - $85.54 $194,601 - $215,988
-2,525 Reduced 77.76%
722 $61.8 Million
Q1 2017

Aug 12, 2024

SELL
N/A
-291 Reduced 28.73%
722 $60.7 Million
Q4 2016

Aug 12, 2024

SELL
N/A
-2,234
1,013 $74.5 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $805B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Glen Eagle Advisors, LLC Portfolio

Follow Glen Eagle Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Glen Eagle Advisors, LLC with notifications on news.